22 stories mentioning RMDUpdated just now
Every FINWIRES story that references RMD, newest first.
ResMed (RMD) has an average rating of overweight and mean price target of $263.08, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $211.92, Change: $-11.32, Percent Change: -5.07%
ResMed (RMD) has an average rating of overweight and mean price target of $263.08, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $211.92, Change: $-11.32, Percent Change: -5.07%
(Updates with economic data, recent oil price movement, world markets' overview and corporate stock movements.)US equity futures were edging higher pre-bell Friday as traders assessed July's national jobs report and monitored developments in the Middle East conflict.Dow Jones Industrial Average futures were 0.1% higher, S&P 500 futures were up 0.3%, and Nasdaq futures were 0.6% higher.Iran released a draft plan for the Strait of Hormuz that restricts US and Israeli ships from passage, while other nations that harmed it would not be allowed to transit the waterway until compensation is paid, CNBC reported, citing Iranian state news outlet Fars. Iran and Oman are reportedly close to an agreement regarding passage through the strait.In the latest round of earnings, Vistra (VST) reported a decline in Q2 net income and operating revenue.Oil prices were lower, with front-month global benchmark North Sea Brent crude down 1% at $81.69 per barrel and US West Texas Intermediate crude 0.7% lower at $76.77 per barrel.The July national unemployment rate was reported at 4.1%, down from 4.2% in the prior month and lower than the 4.2% figure from estimates compiled by Bloomberg.Federal Reserve Richmond President Thomas Barkin is slated to speak on Friday.In other world markets, Japan's Nikkei closed 0.1% lower, Hong Kong's Hang Seng ended 0.5% higher, and China's Shanghai Composite finished 1% higher. Meanwhile, the UK's FTSE 100 was up 0.7%, and Germany's DAX index was 0.9% higher in Europe's early afternoon session.In equities, Advanced Micro Devices (AMD) shares rose 2.2% after the company said it agreed to purchase Taalas to expand its computing capabilities with specialized artificial intelligence processors. Airbnb (ABNB) stock was up 7.5% after the company's Q2 results surpassed analysts' estimates amid strong demand fueled by the FIFA World Cup. Cloudflare (NET) shares surged 16% after the company lifted its full-year outlook following better-than-expected Q2 results.On the losing side, Resmed (RMD) shares fell 11% despite the company reporting higher fiscal Q4 adjusted earnings and revenue.
ResMed (RMD) is expected to post strong fiscal Q4 earnings growth, helped by an 8.6% rise in sales and gains in gross margins, UBS Securities said Monday in a report.US sales of sleep-apnea devices may continue to cool, reflecting a mature market rather than a meaningful impact from GLP-1 weight-loss drugs, the report said.UBS said a production problem affecting ResMed's Astral ventilators is likely to weigh on fiscal 2027 results. The company has issued a field safety notice and is directing all output toward replacing affected units, limiting availability for normal sales. The size of the sales impact is unclear, the report said.UBS trimmed its fiscal 2027 EPS estimate by about 1% to reflect ResMed's sale of MatrixCare, and raised its buyback assumption to $880 million from $800 million.Fiscal Q4 earnings are due Aug. 6.UBS cut its price target on ResMed stock to $300 from $312 and maintained its buy rating.Price: $195.12, Change: $-3.50, Percent Change: -1.76%
ResMed (RMD) has an average rating of overweight and mean price target of $266.02, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
ResMed (RMD) has an average rating of overweight and mean price target of $267.94, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $198.14, Change: $+5.13, Percent Change: +2.66%
ResMed (RMD) has an average rating of overweight and mean price target of $269.05, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Michael J. Farrell, Director, Chairman and Chief Executive Officer, on July 07, 2026, sold 4,991 shares in Resmed (RMD) for $1,090,771. Following the Form 4 filing with the SEC, Farrell has control over a total of 468,313 common shares of the company, with 466,223 shares held directly and 2,090 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/943819/000094381926000038/xslF345X05/form4.xml
ResMed (RMD) is selling its MatrixCare business for a "cheap" price of $490 million, but the transaction is not material to the company's outlook, RBC Capital Markets said in a note Wednesday.The brokerage said that while it was unlikely that MatrixCare would be sold at the 25x EV/EBITDA multiple at which it was acquired in 2018, a low double-digit to mid-teens multiple might have been achievable, compared with the 8.4x multiple at which it was sold.The low multiple at which MatrixCare was sold raises questions about future artificial intelligence disruptions to ResMed's software business, according to the note.The transaction did not surprise, though, as MatrixCare was detracting from the overall growth of ResMed's residential care software segment, the brokerage said.RBC retained an outperform rating on the stock, but lowered its price target to $276 from $321.Shares of ResMed were down 4.9% in Wednesday trading.Price: $209.08, Change: $-10.67, Percent Change: -4.86%
Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index falling 1.3% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1.8%.The iShares Biotechnology ETF (IBB) rose 0.7%.In corporate news, ResMed (RMD) shares fell 4.5% after Morgan Stanley downgraded the company to equalweight from overweight and cut its price target to $230 from $286.UniQure (QURE) shares surged 76% after the company said that it intends to submit a Biologics License Application for the accelerated approval of AMT-130 to treat Huntington's disease in Q3.Novo Nordisk (NVO) said it is aware of claims by cyber extortion group FulcrumSec that it stole company data and sought a $25 million payment, Reuters reported. Novo shares were up 0.2%.Moderna (MRNA) plans to invest in production sites in Germany and is interested in the plants that BioNTech (BNTX) has slated for closure, according to a Google translation of a Wednesday report from German news outlet Handelsblatt. Moderna shares jumped almost 11%, and BioNTech was up 2.3%.
Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index falling 1% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1.3%.The iShares Biotechnology ETF (IBB) rose 1.3%.In corporate news, ResMed (RMD) shares fell 4.3% after Morgan Stanley downgraded the company to equalweight from overweight and cut its price target to $230 from $286.
ResMed (RMD) shares were down about 4% in Wednesday trading after Morgan Stanley downgraded the stock to equal weight from overweight and cut its price target to $230 from $286.Trading volume stood at more than 1.0 million shares, compared with a daily average of about 1.3 million.Price: $186.15, Change: $-7.79, Percent Change: -4.02%
Michael J. Farrell, Director, Chairman and CEO, on June 08, 2026, sold 4,991 shares in Resmed (RMD) for $968,064. Following the Form 4 filing with the SEC, Farrell has control over a total of 468,346 common shares of the company, with 466,256 shares held directly and 2,090 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/943819/000094381926000035/xslF345X05/form4.xmlPrice: $196.82, Change: $+3.68, Percent Change: +1.91%
Michael J. Farrell, Director, Chairman and Chief Executive Officer, on May 07, 2026, sold 4,991 shares in Resmed (RMD) for $1,037,233. Following the Form 4 filing with the SEC, Farrell has control over a total of 468,313 common shares of the company, with 466,223 shares held directly and 2,090 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/943819/000094381926000030/xslF345X05/form4.xml
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We cut our target to $180 from $234, 15.0x our FY 27 EPS estimate, a discount to its 10-year historical forward P/E average. We keep our FY 26 EPS view at $11.03 and our FY 27 view at $12.00. Despite beating Q3 earnings expectations, RMD faces several headwinds that concern us. During the Q3 analyst call, RMD acknowledged emerging component cost pressures and rising fuel costs stemming from Middle East geopolitical uncertainty, with the outgoing, long-tenured CFO Brett Sandercock signaling a challenging margin environment. Amid a complex operating environment, and the proposed $340M acquisition of Noctrix Health, which may carry some execution risks, RMD is going through an important leadership transition with the long-tenured CFO who held the role for 20 years, retiring effective May 4, and replaced by A. Bloomer, who was previously the CFO of Exact Sciences (recently acquired by Abbott). These factors, combined with broader macro uncertainties, may put pressure on RMD's near-term performance, in our view.
ResMed (RMD) has an average rating of overweight and mean price target of $286.27, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $202.74, Change: $-11.07, Percent Change: -5.18%
ResMed (RMD) has an average rating of overweight and mean price target of $286.27, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $204.27, Change: $-9.54, Percent Change: -4.46%
ResMed (RMD) has an average rating of overweight and mean price target of $286.27 according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $201.18, Change: $-12.57, Percent Change: -5.88%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:ResMed delivered mixed Q3 FY 26 results with revenue growing 11% to $1.43B, $20M below expectations, while non-GAAP EPS of $2.86 rose 21%, beating consensus by $0.06. Geographic performance showed broad strength with U.S./Canada/Latin America up 9% and Europe/Asia expanding 16%, while masks/accessories outpaced devices with 16% vs 9% growth. The standout highlight was gross margin expansion of 290 bps to 62.2% driven by manufacturing efficiencies and component cost improvements, demonstrating operational excellence in our view. The company continues advancing its digital health strategy with new product launches including the AirTouch F30i mask and plans for a 2027 Indiana distribution center. We expect the recently completed VirtuOx acquisition to strengthen diagnostic capabilities within ResMed's digital health ecosystem across 140+ countries, positioning the company well for continued growth in the expanding sleep and respiratory care market.
ResMed (RMD) has an average rating of overweight and mean price target of $298.71, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $220.36, Change: $+0.51, Percent Change: +0.23%
Showing 1-20 of 22
